Kezar Life Sciences, Inc. (Nasdaq:KZR)103% HIGHER; reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome...
Source LinkKezar Life Sciences, Inc. (Nasdaq:KZR)103% HIGHER; reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome...
Source Link
Comments